The reversible EGFR tyrosine kinase inhibitors gefitinib and erlotinib are commonly used in lung cancer treatment, but they failed to demonstrate an overall clinical benefit in recurrent glioblastoma [38,39]. Here, EGFR is linked to lung cancer.